FindTrial
Sign In

A Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies

A Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221827
Enrollment
Unknown
Registered
2012-06-18
Start date
2012-06-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Cancer, Advanced B Cell Malignancies

Interventions

investigational material(s) Generic name etc : MEDI-551 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material

Sponsors

AstraZeneca
Lead Sponsor
MedImmune LLC
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Japanese men or women at least 20 years of age - Histologically confirmed CLL (excluding small lymphocytic lymphoma (SLL)), DLBCL, FL, or MM. - Karnofsky Performance Status: 70 or more - Life expectancy of 12 weeks or more

Exclusion criteria

Exclusion criteria: - Any available standard line of therapy known to be life-prolonging or life-saving - Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for treatment of cancer - Previous therapy directed against CD19, such as monoclonal antibodies or Mab conjugates

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026